A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

References

• Al-Harbi, K. S. 2012. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence 369:369. doi:10.2147/PPA.S29716.
   Google Scholar
• Anderson, B. T., A. Danforth, P. R. Daroff, C. Stauffer, E. Ekman, G. Agin-Liebes, A. Trope, M. T. Boden, P. J. Dilley, J. Mitchell, et al. 2020. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27:100538. doi:10.1016/j.eclinm.2020.100538.
   PubMedGoogle Scholar
• Bai, Z., S. Luo, L. Zhang, S. Wu, and I. Chi. 2020. Acceptance and Commitment Therapy (ACT) to reduce depression: A systematic review and meta-analysis. Journal of Affective Disorders 260:728–37. doi:10.1016/j.jad.2019.09.040.
   PubMed Web of Science ®Google Scholar
• Barba, T., S. Buehler, H. Kettner, C. Radu, B. G. Cunha, D. J. Nutt, D. Erritzoe, L. Roseman, and R. Carhart-Harris. 2022. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open 8 (5):e163. doi:10.1192/bjo.2022.565.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Belló, M., M. E. Medina-Mora, M. E. Medina-Mora, and R. Lozano. 2005. [Prevalence and diagnosis of depression in Mexico]. Salud Pública de México 47 Suppl 1:S4–11.
   PubMed Web of Science ®Google Scholar
• Bobo, W. V., G. C. Angleró, G. Jenkins, D. K. Hall-Flavin, R. Weinshilboum, and J. M. Biernacka. 2016. Validation of the 17-item hamilton depression rating scale definition of response for adults with major depressive disorder using equipercentile linking to clinical global impression scale ratings: Analysis of pharmacogenomic research network antidepressa: Validation of HDRS definition of response. Human Psychopharmacology: Clinical & Experimental 31 (3):185–92. doi:10.1002/hup.2526.
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., M. P. Bradstreet, F. S. Barrett, K. A. MacLean, R. Jesse, M. W. Johnson, and R. R. Griffiths. 2016. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology 30 (12):1268–78. doi:10.1177/0269881116662634.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, et al. 2018. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology 235 (2):399–408. doi:10.1007/s00213-017-4771-x.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, A. Feilding, et al. 2016. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry 3 (7):619–27. doi:10.1016/S2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• Catalfomo, P., and V. E. Tyler. 1964. The production in submerged culture by Psilocybe cubensis. Lloydia 27:53–63.
   Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78 (5):481. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, S. So, N. Gukasyan, T. C. Swift, and R. R. Griffiths. 2021. Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology 35 (4):437–46. doi:10.1177/0269881120967878.
   PubMed Web of Science ®Google Scholar
• Dawood Hristova, J. J., and V. Pérez-Jover. 2023. Psychotherapy with psilocybin for depression: Systematic review. Behavioral Sciences 13 (4):297. doi:10.3390/bs13040297.
   Web of Science ®Google Scholar
• Daws, R. E., C. Timmermann, B. Giribaldi, J. D. Sexton, M. B. Wall, D. Erritzoe, L. Roseman, D. Nutt, and R. Carhart-Harris. 2022. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine 28 (4):844–51. doi:10.1038/s41591-022-01744-z.
   PubMed Web of Science ®Google Scholar
• Dittrich, A. 1998. The standardized psychometric assessment of Altered States of Consciousness (ASCs) in Humans. Pharmacopsychiatry 31 (S 2):80–84. doi:10.1055/s-2007-979351.
   PubMed Web of Science ®Google Scholar
• Ferrari, A. J., F. J. Charlson, R. E. Norman, A. D. Flaxman, S. B. Patten, T. Vos, H. A. Whiteford, and J. B. Potash. 2013. The epidemiological modelling of major depressive disorder: Application for the global burden of disease study 2010. PLoS ONE 8 (7):e69637. doi:10.1371/journal.pone.0069637.
   PubMed Web of Science ®Google Scholar
• Fricke, J., C. Lenz, J. Wick, F. Blei, and D. Hoffmeister. 2019. Production options for psilocybin: making of the magic. Chemistry - A European Journal 25 (4):897–903. doi:10.1002/chem.201802758.
   PubMed Web of Science ®Google Scholar
• Gasser, P. 2022. Psychedelic group therapy. In Disruptive psychopharmacology, ed. F. S. Barrett and K. H. Preller, 23–34. Springer International Publishing. doi: 10.1007/7854_2021_268.
   Google Scholar
• González-Trujano, M. E. M., L. Ana, A. Reyes-Ramírez, B. Reyes-Trejo, and A. Navarrete. 2006. Palmitone isolated from annona diversifolia induces an anxiolytic-like effect in mice. Planta Medica 72 (8):703–07. doi:10.1055/s-2006-931598.
   PubMed Web of Science ®Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, C. Bird, R. E. Blom, C. Brennan, D. Brusch, et al. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387 (18):1637–48. doi:10.1056/NEJMoa2206443.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Gukasyan, N., A. K. Davis, F. S. Barrett, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, and R. R. Griffiths. 2022. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36 (2):151–58. doi:10.1177/02698811211073759.
   PubMed Web of Science ®Google Scholar
• Guzman, G. 2005. Species diversity of the genus Psilocybe (basidiomycotina, agaricales, strophariaceae) in the world mycobiota, with special attention to hallucinogenic properties. International Journal of Medicinal Mushrooms 7 (1–2):305–32. doi:10.1615/IntJMedMushr.v7.i12.280.
   Google Scholar
• Johnson, M. W., R. R. Griffiths, P. S. Hendricks, and J. E. Henningfield. 2018. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology 142:143–66. doi:10.1016/j.neuropharm.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Klein, A. K., M. Chatha, L. J. Laskowski, E. I. Anderson, S. D. Brandt, S. J. Chapman, J. D. McCorvy, and A. L. Halberstadt. 2021. Investigation of the structure-activity relationships of psilocybin analogues. ACS Pharmacology and Translational Science 4 (2):533–42. doi:10.1021/acsptsci.0c00176.
   PubMedGoogle Scholar
• Koike, Y., K. Wada, G. Kusano, S. Nozoe, and K. Yokoyama. 1981. Isolation of psilocybin from Psilocybe argentipes and its determination in specimens of some mushrooms. Journal of Natural Products 44 (3):362–65. doi:10.1021/np50015a023.
   Web of Science ®Google Scholar
• Ko, K., E. I. Kopra, A. J. Cleare, and J. J. Rucker. 2023. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders 322:194–204. doi:10.1016/j.jad.2022.09.168.
   PubMed Web of Science ®Google Scholar
• Lenz, C., A. Sherwood, R. Kargbo, and D. Hoffmeister. 2021. Taking different roads: L ‐Tryptophan as the origin of Psilocybe natural products. ChemPluschem 86 (1):28–35. doi:10.1002/cplu.202000581.
   PubMed Web of Science ®Google Scholar
• Lenz, C., J. Wick, and D. Hoffmeister. 2017. Identification of ω- N -Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybe Natural Product. Journal of Natural Products 80 (10):2835–38. doi:10.1021/acs.jnatprod.7b00407.
   PubMed Web of Science ®Google Scholar
• Lowe, H., N. Toyang, B. Steele, H. Valentine, J. Grant, A. Ali, W. Ngwa, and L. Gordon. 2021. The therapeutic potential of psilocybin. Molecules 26 (10):2948. doi:10.3390/molecules26102948.
   PubMed Web of Science ®Google Scholar
• MacLean, K. A., J.-M. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Maier, W. 1990. The hamilton depression scale and its alternatives: A comparison of their reliability and validity. In The Hamilton Scales, ed. P. Bech and A. Coppen, 64–71. Springer. doi:10.1007/978-3-642-75373-2_8.
   Google Scholar
• Minero Ortega, F. (2012). Las mujeres sabias y las Veladas con “hongos sagrados”: el chamanismo mazateco (Doctoral dissertation, Tesis de Licenciatura, ENAH-INAH, México).
   Google Scholar
• Modlin, N. L., T. M. Miller, J. J. Rucker, N. Kirlic, M. Lennard-Jones, D. Schlosser, and S. T. Aaronson. 2023. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of Affective Disorders 326:18–25. doi:10.1016/j.jad.2023.01.077.
   PubMed Web of Science ®Google Scholar
• Moreno-Pérez, G. F., M. E. González-Trujano, A. Hernandez-Leon, M. G. Valle-Dorado, A. Valdés-Cruz, N. Alvarado-Vásquez, E. Aguirre-Hernández, H. Salgado-Ceballos, and F. Pellicer. 2023. Antihyperalgesic and antiallodynic effects of amarisolide a and Salvia amarissima ortega in experimental fibromyalgia-type pain. Metabolites 13 (1):59. doi:10.3390/metabo13010059.
   Web of Science ®Google Scholar
• Nicholas, C. R., K. M. Henriquez, M. C. Gassman, K. M. Cooper, D. Muller, S. Hetzel, R. T. Brown, N. V. Cozzi, C. Thomas, and P. R. Hutson. 2018. High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology (Oxford, England) 32 (7):770–78. doi:10.1177/0269881118780713.
   PubMed Web of Science ®Google Scholar
• Page, L. A., A. Rehman, H. Syed, K. Forcer, and G. Campbell. 2021. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Frontiers in Psychiatry 12:743599. doi:10.3389/fpsyt.2021.743599.
   PubMed Web of Science ®Google Scholar
• Peill, J. M., K. E. Trinci, H. Kettner, L. J. Mertens, L. Roseman, C. Timmermann, F. E. Rosas, T. Lyons, and R. L. Carhart-Harris. 2022. Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology 36 (1):31–45. doi:10.1177/02698811211066709.
   PubMed Web of Science ®Google Scholar
• Ponomarenko, P., F. Seragnoli, A. Calder, P. Oehen, and G. Hasler. 2023. Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. Journal of Psychopharmacology 37 (7):660–78. doi:https://doi.org/10.1177/02698811231155117.
   PubMed Web of Science ®Google Scholar
• Porsolt, R. D., A. Bertin, and M. Jalfre. 1977. Behavioral despair in mice: A primary screening test for antidepressants. Archives Internationales de Pharmacodynamie Et de Therapie 229 (2):327–36.
   PubMedGoogle Scholar
• Rafati, H., H. Riahi, and A. Mohammadi. 2009. Enhancement of indole alkaloids produced by Psilocybe cubensis (earle) singer (agaricomycetideae) in controlled harvesting light conditions. International Journal of Medicinal Mushrooms 11 (4):419–26. doi:10.1615/IntJMedMushr.v11.i4.80.
   Web of Science ®Google Scholar
• Ramos-Brieva, J. A., and A. Cordero-Villafafila. 1988. A new validation of the hamilton rating scale for depression. Journal of Psychiatric Research 22 (1):21–28. doi:10.1016/0022-3956(88)90024-6.
   PubMed Web of Science ®Google Scholar
• Riba, J., A. Rodrı́guez-Fornells, R. J. Strassman, and M. J. Barbanoj. 2001. Psychometric assessment of the hallucinogen rating scale☆. Drug and Alcohol Dependence 62 (3):215–23. doi:10.1016/S0376-8716(00)00175-7.
   PubMed Web of Science ®Google Scholar
• Roberts, C. A., I. Osborne-Miller, J. Cole, S. H. Gage, and P. Christiansen. 2020. Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use. Journal of Psychopharmacology 34 (9):999–1007. doi:10.1177/0269881120936508.
   PubMed Web of Science ®Google Scholar
• Rosenblat, J. D., M. I. Husain, Y. Lee, R. S. McIntyre, R. B. Mansur, D. Castle, H. Offman, S. V. Parikh, B. N. Frey, A. Schaffer, et al. 2023. The canadian network for mood and anxiety treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder. The Canadian Journal of Psychiatry 68 (1):5–21. doi:10.1177/07067437221111371.
   PubMed Web of Science ®Google Scholar
• Ruan-Soto, F. 2007. 50 años de etnomicología en México. Lacandonia 1 (1):97–108.
   Google Scholar
• Santomauro, D. F., A. M. Mantilla Herrera, J. Shadid, P. Zheng, C. Ashbaugh, D. M. Pigott, C. Abbafati, C. Adolph, J. O. Amlag, A. Y. Aravkin, et al. 2021. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet 398 (10312):1700–12. doi:10.1016/S0140-6736(21)02143-7.
   PubMed Web of Science ®Google Scholar
• Sforzini, L., C. Worrell, M. Kose, I. M. Anderson, B. Aouizerate, V. Arolt, M. Bauer, B. T. Baune, P. Blier, A. J. Cleare, et al. 2022. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry 27 (3):1286–99. doi:10.1038/s41380-021-01381-x.
   PubMed Web of Science ®Google Scholar
• Sloshower, J., J. Guss, R. Krause, R. M. Wallace, M. T. Williams, S. Reed, and M. D. Skinta. 2020. Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. Journal of Contextual Behavioral Science 15:12–19. doi:10.1016/j.jcbs.2019.11.002.
   Web of Science ®Google Scholar
• Sommano, S. R., R. Suksathan, T. Sombat, P. Seehanam, S. Sirilun, W. Ruksiriwanich, S. Wangtueai, and N. Leksawasdi. 2022. Novel perspective of medicinal mushroom cultivations: A review case for ‘magic’ mushrooms. Agronomy 12 (12):3185. doi:10.3390/agronomy12123185.
   Google Scholar
• Strumila, R., B. Nobile, L. Korsakova, A. Lengvenyte, E. Olie, J. Lopez-Castroman, S. Guillaume, and P. Courtet. 2021. Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors. Pharmaceuticals 14 (12):1213. doi:10.3390/ph14121213.
   Web of Science ®Google Scholar
• Studerus, E., A. Gamma, F. X. Vollenweider, and V. Bell. 2010. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5 (8):e12412. doi:10.1371/journal.pone.0012412.
   PubMed Web of Science ®Google Scholar
• Trope, A., B. T. Anderson, A. R. Hooker, G. Glick, C. Stauffer, and J. D. Woolley. 2019. Psychedelic-assisted group therapy: A systematic review. Journal of Psychoactive Drugs 51 (2):174–88. doi:10.1080/02791072.2019.1593559.
   PubMed Web of Science ®Google Scholar
• Twohig, M. P., and M. E. Levin. 2017. Acceptance and commitment therapy as a treatment for anxiety and depression. Psychiatric Clinics of North America 40 (4):751–70. doi:10.1016/j.psc.2017.08.009.
   PubMed Web of Science ®Google Scholar
• van Amsterdam, J., A. Opperhuizen, and W. van den Brink. 2011. Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology 59 (3):423–29. doi:10.1016/j.yrtph.2011.01.006.
   PubMed Web of Science ®Google Scholar
• Van Court, R. C., M. S. Wiseman, K. W. Meyer, D. J. Ballhorn, K. R. Amses, J. C. Slot, B. T. M. Dentinger, R. Garibay-Orijel, and J. K. Uehling. 2022. Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biology 126 (4):308–19. doi:10.1016/j.funbio.2022.01.003.
   PubMed Web of Science ®Google Scholar
• Vargas, A. S., Â. Luís, M. Barroso, E. Gallardo, and L. Pereira. 2020. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases—A systematic review and meta-analysis of clinical trials. Biomedicines 8 (9):331. doi:10.3390/biomedicines8090331.
   PubMed Web of Science ®Google Scholar
• Voineskos, D., Z. J. Daskalakis, and D. M. Blumberger. 2020. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatric Disease and Treatment 16:221–34. doi:10.2147/NDT.S198774.
   PubMed Web of Science ®Google Scholar
• Wagner, H., and S. Bladt. 1996. Alcaloid drugs. In Plant drug analysis, Springer: Berlin, Heidelberg. doi:10.1007/978-3-642-00574-9.
   Google Scholar
• Yu, C.-L., C.-S. Liang, F.-C. Yang, Y.-K. Tu, C.-W. Hsu, A. F. Carvalho, B. Stubbs, T. Thompson, C.-K. Tsai, T.-C. Yeh, et al. 2022. Trajectory of antidepressant effects after single- or two-dose administration of psilocybin: A systematic review and multivariate meta-analysis. Journal of Clinical Medicine 11 (4):938. doi:10.3390/jcm11040938.
   PubMed Web of Science ®Google Scholar